Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Asset Writedowns and Impairment: 2015-2024

Historic Asset Writedowns and Impairment for Theravance Biopharma (TBPH) over the last 2 years, with Sep 2024 value amounting to $1.6 million.

  • Theravance Biopharma's Asset Writedowns and Impairment was N/A to $1.6 million in Q3 2024 from the same period last year, while for Sep 2024 it was $10.3 million, marking a year-over-year change of. This contributed to the annual value of $4.5 million for FY2024, which is N/A change from last year.
  • As of Q3 2024, Theravance Biopharma's Asset Writedowns and Impairment stood at $1.6 million, which was up 1,510.31% from $97,000 recorded in Q4 2017.
  • In the past 5 years, Theravance Biopharma's Asset Writedowns and Impairment ranged from a high of $1.6 million in Q3 2024 and a low of $1.6 million during Q3 2024.
  • Its 1-year average for Asset Writedowns and Impairment is $1.6 million, with a median of $1.6 million in 2024.